Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419662PMC
http://dx.doi.org/10.14309/crj.0000000000001117DOI Listing

Publication Analysis

Top Keywords

schistosomiasis unexpected
4
unexpected gastrointestinal
4
gastrointestinal bleeding
4
bleeding revealed
4
revealed endoscopic
4
endoscopic biopsy
4
schistosomiasis
1
gastrointestinal
1
bleeding
1
revealed
1

Similar Publications

Background: Intestinal schistosomiasis was confirmed endemic in Mangochi District, Malawi, in May of 2018 following an unexpected encounter with discreet populations of Biomphalaria spp. freshwater snails during routine malacological surveillance activities. Since then, only limited malacological surveillance of Biomphalaria has been carried out, and so the distribution of Biomphalaria populations in this area is currently unclear.

View Article and Find Full Text PDF

Aryl hydantoins were identified in the early 1980s as a promising antischistosomal chemotype. However, as exemplified by Ro 13-3978, this compound series produced antiandrogenic side effects on the host, a not unexpected outcome given their structural similarity to the antiandrogenic drug nilutamide. The two key advances in our optimization of Ro 13-3978 were swapping the aryl trifluoromethyl substituent with a difluoroethyl to abolish antiandrogenic effects and replacing the hydrogen atoms of the -dimethyl substructure with deuterium atoms to increase metabolic stability.

View Article and Find Full Text PDF

A 57-year-old black male patient was admitted with flatulence and post-prandial fullness a month ago. No other gastrointestinal complaints. He had history of arterial hypertension, medicated with nifedipine 30mg/day and hydrochlorthiazide 50mg/day, and had been diagnosed and treated for malaria a week before admission.

View Article and Find Full Text PDF

Pyridine nucleotide-disulfide oxidoreductases are underexplored as drug targets, and thioredoxin reductases (TrxRs) stand out as compelling pharmacological targets. Selective TrxR inhibition is challenging primarily due to the reliance on covalent inhibition strategies. Recent studies identified a regulatory and druggable pocket in thioredoxin glutathione reductase (TGR), a TrxR-like enzyme, and an established drug target for schistosomiasis.

View Article and Find Full Text PDF

Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis.

PLoS Pathog

August 2024

Laboratório de Inflamação, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Identifying new molecular therapies targeted at the severe hepatic fibrosis associated with the granulomatous immune response to Schistosoma mansoni infection is essential to reduce fibrosis-related morbidity/mortality in schistosomiasis. In vitro cell activation studies suggested the lipid molecule prostaglandin D2 (PGD2) as a potential pro-fibrotic candidate in schistosomal context, although corroboratory in vivo evidence is still lacking. Here, to investigate the role of PGD2 and its cognate receptor DP2 in vivo, impairment of PGD2 synthesis by HQL-79 (an inhibitor of the H-PGD synthase) or DP2 receptor inhibition by CAY10471 (a selective DP2 antagonist) were used against the fibrotic response of hepatic eosinophilic granulomas of S.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!